Long-acting HIV medication for compassionate use
Part of Immune system & allergy, Infections clinical trials.
This trial provides cabotegravir, a long-acting injectable HIV medicine, for people who cannot take or absorb oral HIV medications. It is for those who have no other effective treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and are 18 years or older
- You cannot build a working treatment plan with available HIV medications
- You cannot take oral HIV pills or need a long-acting injectable medicine due to problems like poor absorption
- Good adherence to daily pills is not enough reason to join—you must have a medical need
- If you are a woman who could become pregnant, you must use effective contraception and avoid pregnancy during and for 52 weeks after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study tests how a long-acting injectable HIV prevention drug (cabotegravir) works in people who also use hormone therapy (like birth control or gender-affirming hormones). The goal is to see if the hormones affect how well the drug prevents HIV. If you are HIV-negative, use hormones, and meet other health criteria, you may be able to join.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
Hear when a new Infection, Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.